Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy
Annals of Clinical and Translational Neurology · 2024
DOI: 10.1002/acn3.52182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Mie Waede und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Killer Cells, Natural. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Scleroseforeningen, Lundbeck Foundation, Jascha Fonden.
Abstract (Originalsprache)
Objective
Anti‐CD20 therapy is a highly effective treatment for multiple sclerosis (MS). In this study, we investigated MS‐related changes in peripheral blood mononuclear cell (PBMC) subsets compared to healthy controls and longitudinal changes related to the treatment.
Methods
Multicolor spectral flow cytometry analysis was performed on 78 samples to characterize disease‐ and treatment‐related PBMC clusters. Blood samples from MS patients were collected at baseline and up to 8 months post‐treatment, with three collection points after treatment initiation. Unsupervised clustering tools and manual gating were applied to identify subclusters of interest and quantify changes.
Results
B cells were depleted from the periphery after anti‐CD20 treatment as expected, and we observed an isolated acute, transitory drop in the proportion of natural killer (NK) and NKT cells among the main populations of PBMC ( P = 0.03, P = 0.004). Major affected PBMC subpopulations were cytotoxic immune cells (NK, NKT, and CD8 + T cells), and we observed a higher proportion of cytotoxic cells with reduced brain‐homing ability and a higher regulatory function as a long‐term anti‐CD20‐related effect. Additionally, anti‐CD20 therapy altered distributions of memory CD8 + T cells and reduced exhaustion markers in both CD4 + and CD8 + T cells.
Interpretation
The findings of this study elucidate phenotypic clusters of NK and CD8 + T cells, which have previously been underexplored in the context of anti‐CD20 therapy. Phenotypic modifications towards a more regulatory and controlled phenotype suggest that these subpopulations may play a critical and previously unrecognized role in mediating the therapeutic efficacy of anti‐CD20 treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Odense University Hospital, Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
- Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
- Section for Experimental and Translational Immunology, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
- Danish Institute for Advanced Study, University of Southern Denmark, Odense, Denmark.
- Institute for Computational Systems Biology, University of Hamburg, Hamburg, Germany.
ORCID-Profile: Mie Waede, Lasse F Voss, Jesper B Moeller, Maria L Elkjaer, Zsolt Illes
Förderung
- Scleroseforeningen
- Lundbeck Foundation
- Jascha Fonden
- Novo Nordisk
- Danish Regions
Zitieren
APA
Waede, M., Voss, L. F., Kingo, C., Moeller, J. B., Elkjaer, M. L., & Illes, Z. (2024). Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52182
Vancouver
Waede M, Voss LF, Kingo C, Moeller JB, Elkjaer ML, Illes Z. Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52182
BibTeX
@article{Waede2024,
author = {Waede, Mie and Voss, Lasse F and Kingo, Christina and Moeller, Jesper B and Elkjaer, Maria L and Illes, Zsolt},
title = {Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti‐CD20 therapy},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
doi = {10.1002/acn3.52182}
}
EUVIMED